ALYSIA TSUI: Open Payments
NPI 1992428973 · HILLSBOROUGH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,734 in 39 payments from 11 companies in 2025. Trend: 2023 $955 · 2024 $1,331 · 2025 $1,734
Food & beverage: $1,734
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $389 |
| Janssen Biotech, Inc. | 4 | $306 |
| Madrigal Pharmaceuticals | 3 | $203 |
| Phathom Pharmaceuticals, Inc. | 3 | $149 |
| GENZYME CORPORATION | 1 | $147 |
| Celltrion USA Inc. | 1 | $122 |
| Novo Nordisk Inc | 1 | $118 |
| Janssen Scientific Affairs, LLC | 1 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Lilly USA, LLC | 4 | $79 |
Products named: TREMFYA, RINVOQ, REZDIFFRA, SKYRIZI, VOQUEZNA, DUPIXENT, ZYMFENTRA, Wegovy.
Industry payments across NJ — which companies pay providers there.
